Syphilis Immunoassay Diagnostics Market Report 2026

The syphilis immunoassay diagnostics market size has grown strongly in recent years. It will grow from $33.5 billion in 2025 to $36.05 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to rising incidence of sexually transmitted infections, expansion of routine screening programs, improved laboratory infrastructure, availability of elisa and clia technologies, growing awareness of early syphilis diagnosis.

The syphilis immunoassay diagnostics market size is expected to see strong growth in the next few years. It will grow to $46.91 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to increasing adoption of rapid diagnostic tests, rising focus on decentralized testing models, expansion of screening in developing regions, growing investments in laboratory automation, increasing demand for high-throughput diagnostic platforms. Major trends in the forecast period include increasing adoption of automated immunoassay analyzers, rising demand for high-sensitivity diagnostic kits, expansion of point-of-care syphilis testing, growing integration of digital laboratory workflows, enhanced focus on early and accurate disease detection.

The increasing prevalence of sexually transmitted diseases is expected to drive the growth of the syphilis immunoassay diagnostics market in the coming years. Sexually transmitted diseases (STDs), also known as sexually transmitted infections (STIs), are infections primarily transmitted through sexual activity, including vaginal, anal, and oral sex. The rise in STDs is linked to factors such as reduced condom use, antibiotic resistance, lack of sexual education, social and behavioral changes, stigma, decreased funding for STD programs, and increased travel. Syphilis immunoassay diagnostics play a crucial role in detecting and managing sexually transmitted infections by providing accurate and timely identification of syphilis, enabling appropriate treatment and prevention strategies. For example, in June 2024, according to a report by the Terrence Higgins Trust, a UK-based organization, the UK Health Security Agency (UKHSA) recorded 401,800 sexually transmitted infections (STIs) in England in 2023, marking a 5% increase compared to the previous year. Therefore, the rising incidence of STDs is fueling growth in the syphilis immunoassay diagnostics market.

Key companies in the syphilis immunoassay diagnostics market are focusing on innovative solutions, such as rapid syphilis tests, to improve the speed and accuracy of detection. Rapid syphilis tests are simple, point-of-care devices that detect syphilis antibodies in blood or bodily fluids within minutes, allowing for quick diagnosis and early treatment. For instance, in February 2023, Chembio Diagnostics Inc., a US-based point-of-care diagnostics company specializing in infectious diseases, received a CLIA waiver from the FDA for its DPP HIV-Syphilis System. This dual rapid test is designed to simultaneously detect antibodies to HIV 1/2 and Treponema pallidum, the bacteria that causes syphilis. The 15-minute test aims to enhance diagnosis and treatment, particularly to prevent mother-to-child transmission of syphilis and reduce HIV risk among individuals with syphilis.

In April 2023, Biosynex SA, a France-based company providing syphilis immunoassay diagnostics, acquired Chembio Diagnostics Inc. for $17.2 million. This acquisition strengthens Biosynex’s presence in the North American market by leveraging Chembio’s FDA-approved products and expertise in rapid diagnostic testing. Chembio Diagnostics Inc. is a US-based point-of-care diagnostics company focused on infectious diseases, including syphilis.

Major companies operating in the syphilis immunoassay diagnostics market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc, Abbott Laboratories, Siemens Healthineers, Becton Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories Inc, Meril Life Sciences Pvt Ltd, Randox Laboratories Ltd, SEKISUI Diagnostics, Trinity Biotech, Fujirebio, CTK Biotech Inc, bioLytical Laboratories Inc, ACON Laboratories Inc, InTec PRODUCTS INC, Quidel Corporation, Alere Inc, Ortho Clinical Diagnostics, DiaSorin Inc, Sekisui Medical, Beckman Coulter.

North America was the largest region in the syphilis immunoassay diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the syphilis immunoassay diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the syphilis immunoassay diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the syphilis immunoassay diagnostics market by increasing costs of imported reagents, assay kits, analyzers, optical components, and electronic modules. Diagnostic laboratories and hospitals in North America and Europe are most affected due to reliance on imported diagnostic technologies, while Asia-Pacific faces higher export-related production costs. These tariffs are increasing test pricing and procurement costs. However, they are also encouraging domestic reagent manufacturing, localized analyzer assembly, and regional diagnostic innovation.

The syphilis immunoassay diagnostics market research report is one of a series of new reports that provides syphilis immunoassay diagnostics market statistics, including syphilis immunoassay diagnostics industry global market size, regional shares, competitors with a syphilis immunoassay diagnostics market share, detailed syphilis immunoassay diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the syphilis immunoassay diagnostics industry. This syphilis immunoassay diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Syphilis immunoassay diagnostics are laboratory tests designed to detect antibodies or antigens associated with Treponema pallidum, the bacterium that causes syphilis. These diagnostics use immunoassay techniques to identify specific immune responses in the blood. The primary purpose of syphilis immunoassay diagnostics is to accurately diagnose syphilis infections, enabling timely and effective treatment.

The main product types in syphilis immunoassay diagnostics include analyzers, reagents, kits, and other products. Analyzers are laboratory devices used to measure and detect the presence of syphilis in samples. Key technologies used include chemiluminescence immunoassay (CLIA), enzyme-linked immunosorbent assay (ELISA), and others. These diagnostics are applied for both men and women and are utilized by end users such as hospitals, blood banks, diagnostic laboratories, and others.

The syphilis immunoassay diagnostics market consists of revenues earned by entities by providing services such as sample collection services, laboratory testing services, point-of-care testing services, and consultation and follow-up services. The market value includes the value of related goods sold by the service provider or included within the service offering. The syphilis immunoassay diagnostics market also consists of sales of rapid plasma reagin (RPR) tests, fluorescent treponemal antibody absorption (FTA-ABS) tests, point-of-care (POC) tests, western blot assays, and multiplex immunoassays. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.